Diabète de type 1 : tous dans les starting blocks pour changer le cours de la maladie.
L'immunité au coeur des diabètes : un aspect central de la SFD 2024.
Focus sur la cellule beta / exploration de la pathogenèse du diabète.
Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
Start to think differently about Type 1 Diabetes by considering the pre-symptomatic stages of the condition and how it affects people of all ages and their families.
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
This infographic summarizes survey data* about the impact that families in Belgium and the Netherlands have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).
Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.2
Vous êtes sur le point de quitter campus.sanofi/be. Sanofi n'est pas responsable du contenu de ce site externe.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.